RATIONALE: Quantitative neuroimaging studies show that different neuroleptics have similar effects on resting metabolism/perfusion in the basal ganglia, but vary in their effect on the cortex, especially in the prefrontal and temporal lobes. These differences may represent signatures of the action of medication on distinctive receptor combinations. OBJECTIVES: This study seeks to determine the effect on cerebral perfusion at rest of low-dose amisulpride, a neuroleptic with a receptor profile relatively selective to dopaminergic D2-receptors and both antidepressant and antipsychotic efficacy. METHODS: Continuous arterial spin labelling in a placebo-controlled, double blind, crossover study at steady state of N = 20 healthy male adults. RESULTS: Relative to placebo, amisulpride was associated with extensive and significant cortical decrements in resting perfusion levels, particularly in the prefrontal lobes (p = 0.01, corrected). Decrements spared the basal ganglia, where perfusion was slightly increased. CONCLUSIONS: In contrast to earlier reports on other neuroleptics, amisulpride was associated with intense cortical perfusion decrements at rest. These results are consistent with an existing model in which dopaminergic blockade is associated not only with metabolism/perfusion increases in the basal ganglia, but also with decreases in the cerebral cortex that in most neuroleptics are compensated by action on other receptor systems. The selective receptor profile of amisulpride may explain the extensive cortical decrements.
RCT Entities:
RATIONALE: Quantitative neuroimaging studies show that different neuroleptics have similar effects on resting metabolism/perfusion in the basal ganglia, but vary in their effect on the cortex, especially in the prefrontal and temporal lobes. These differences may represent signatures of the action of medication on distinctive receptor combinations. OBJECTIVES: This study seeks to determine the effect on cerebral perfusion at rest of low-dose amisulpride, a neuroleptic with a receptor profile relatively selective to dopaminergic D2-receptors and both antidepressant and antipsychotic efficacy. METHODS: Continuous arterial spin labelling in a placebo-controlled, double blind, crossover study at steady state of N = 20 healthy male adults. RESULTS: Relative to placebo, amisulpride was associated with extensive and significant cortical decrements in resting perfusion levels, particularly in the prefrontal lobes (p = 0.01, corrected). Decrements spared the basal ganglia, where perfusion was slightly increased. CONCLUSIONS: In contrast to earlier reports on other neuroleptics, amisulpride was associated with intense cortical perfusion decrements at rest. These results are consistent with an existing model in which dopaminergic blockade is associated not only with metabolism/perfusion increases in the basal ganglia, but also with decreases in the cerebral cortex that in most neuroleptics are compensated by action on other receptor systems. The selective receptor profile of amisulpride may explain the extensive cortical decrements.
Authors: J L Martinot; M L Paillère-Martinot; M F Poirier; M H Dao-Castellana; C Loc'h; B Mazière Journal: Psychopharmacology (Berl) Date: 1996-03 Impact factor: 4.530
Authors: Roberto Viviani; Eun-Jin Sim; Hanna Lo; Sven Richter; Sebastian Haffer; Nadine Osterfeld; Jan Thöne; Petra Beschoner Journal: Neuroimage Date: 2009-02-05 Impact factor: 6.556
Authors: Adrienne C Lahti; Martin A Weiler; Deborah R Medoff; Carol A Tamminga; Henry H Holcomb Journal: Psychiatry Res Date: 2005-05-30 Impact factor: 3.222
Authors: Rowena Handley; Fernando O Zelaya; A A T Simone Reinders; Tiago Reis Marques; Mitul A Mehta; Ruth O'Gorman; David C Alsop; Heather Taylor; Atholl Johnston; Steve Williams; Philip McGuire; Carmine M Pariante; Shitij Kapur; Paola Dazzan Journal: Hum Brain Mapp Date: 2012-03-25 Impact factor: 5.038
Authors: Daniel Paul Eisenberg; Lisa Yankowitz; Angela M Ianni; Dani Y Rubinstein; Philip D Kohn; Catherine E Hegarty; Michael D Gregory; José A Apud; Karen F Berman Journal: Neuropsychopharmacology Date: 2017-04-07 Impact factor: 7.853
Authors: Oliver G Bosch; Fabrizio Esposito; Michael M Havranek; Dario Dornbierer; Robin von Rotz; Philipp Staempfli; Boris B Quednow; Erich Seifritz Journal: Neuropsychopharmacology Date: 2017-05-31 Impact factor: 7.853
Authors: Peter C T Hawkins; Tobias C Wood; Anthony C Vernon; Alessandro Bertolino; Fabio Sambataro; Juergen Dukart; Emilio Merlo-Pich; Celine Risterucci; Hanna Silber-Baumann; Eamonn Walsh; Ndabezinhle Mazibuko; Fernando O Zelaya; Mitul A Mehta Journal: Hum Brain Mapp Date: 2017-10-23 Impact factor: 5.038